Time To Response In Patients With Advanced Anaplastic Lymphoma Kinase (ALK)-Positive Non-Small-Cell Lung Cancer (NSCLC) Receiving Alectinib In The Phase II NP28673 And NP28761 Studies

S. Gadgeel, A.T. Shaw, F. Barlesi, L. Crino, J.C.H. Yang, A.M. Dingemans, D.W. Kim, F. de Marinis, M. Schulz, S.Y. Liu, R. Gupta, V. Smoljanovic, S.H.I. Ou*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

1 Citation (Web of Science)
Original languageEnglish
Pages (from-to)125-130
Number of pages6
JournalLung Cancer: Targets and Therapy
Publication statusPublished - 1 Jan 2019


  • alectinib
  • non-small-cell lung cancer
  • np28673
  • np28761
  • time to response
  • NP28673
  • NP28761

Cite this